Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: FPANS added to FSC resulted in superior outcomes for daytime total nasal symptom scores (D-TNSS) and individual daytime nasal specific symptoms (congestion, rhinorrhea, sneezing, and itching) compared with montelukast plus FSC and placebo plus FSC (p < or = 0.001). Montelukast plus FSC was superior to placebo plus FSC only for D-TNSS and itching and sneezing. Morning PEF, asthma symptoms, and rescue albuterol use improved significantly (p < or = 0.001) in all treatment groups, but improvements were comparable across the treatment groups. CONCLUSION: In patients with persistent asthma treated with FSC, the addition of montelukast or FPANS for the treatment of SAR resulted in no additional improvements in overall asthma control compared with FSC alone. However, FPANS provided superior rhinitis control compared with montelukast. These data suggest that asthma and rhinitis should each be optimally treated.
|
Authors | Robert A Nathan, Steven W Yancey, Kelli Waitkus-Edwards, Barbara A Prillaman, John L Stauffer, Edward Philpot, Paul M Dorinsky, Harold S Nelson |
Journal | Chest
(Chest)
Vol. 128
Issue 4
Pg. 1910-20
(Oct 2005)
ISSN: 0012-3692 [Print] United States |
PMID | 16236835
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Acetates
- Androstadienes
- Anti-Asthmatic Agents
- Cyclopropanes
- Quinolines
- Sulfides
- Fluticasone
- montelukast
|
Topics |
- Acetates
(administration & dosage, therapeutic use)
- Administration, Inhalation
- Adult
- Androstadienes
(administration & dosage, adverse effects, therapeutic use)
- Anti-Asthmatic Agents
(administration & dosage, therapeutic use)
- Asthma
(drug therapy, physiopathology)
- Cyclopropanes
- Female
- Fluticasone
- Forced Expiratory Volume
- Humans
- Male
- Patient Selection
- Quinolines
(administration & dosage, therapeutic use)
- Reproducibility of Results
- Respiratory Distress Syndrome
(chemically induced)
- Respiratory Function Tests
- Rhinitis, Allergic, Perennial
(drug therapy)
- Sleep Wake Disorders
(chemically induced)
- Sulfides
- Treatment Outcome
- Wakefulness
|